Abstract
Schizophrenia is a complex pathology characterized by the occurrence of a variety of symptoms classified as positive, negative and cognitive. Although the exact etiopathogenesis of this disorder has not been unraveled yet, many theories have been endorsed during the last years. Among these, the neurochemical theories have been the most suited, considering the dopaminergic and glutamatergic dysfunctions to be mainly responsible for psychotic symptoms. However, the lack of efficacy of the available drugs, namely antipsychotics, toward negative and cognitive symptoms led to hypothesize alternative approaches. In this regard, the neurodevelopmental theory of schizophrenia has emerged, proposing the association between the occurrence of environmental risk factors in early-life and the development of psychosis in late-life. In particular, exposure to early life stressing situations, such as pre- and peri-natal stress, has been suggested as a risk factor to d evelop psychopathologies in adulthood in people genetically predisposed. A crucial support in favor of this hypothesis came from neurodevelopmental animal models of schizophrenia, such as maternal malnutrition, maternal deprivation, maternal infections as well as post-weaning social isolation rearing. Moreover, data from these models, corroborated by clinical findings, indicate that oxidative and nitrosative stress play a crucial role in the etiopathogenesis of psychiatric disorders. In the present work, we reviewed the recent progress in literature regarding data available from animal models linking oxidative and nitrosative stress to psychiatric disorders in order to evaluate novel biomarkers of pathology as well as novel therapeutical targets.
Keywords: Early life stress, NOX, NOS, psychiatric disorders, NMDA receptors, nitric oxide, social isolation, maternal stress.
Current Pharmaceutical Design
Title:Early Life and Oxidative Stress in Psychiatric Disorders: What Can we Learn From Animal Models?
Volume: 21 Issue: 11
Author(s): Emanuela Mhillaj, Maria Grazia Morgese and Luigia Trabace
Affiliation:
Keywords: Early life stress, NOX, NOS, psychiatric disorders, NMDA receptors, nitric oxide, social isolation, maternal stress.
Abstract: Schizophrenia is a complex pathology characterized by the occurrence of a variety of symptoms classified as positive, negative and cognitive. Although the exact etiopathogenesis of this disorder has not been unraveled yet, many theories have been endorsed during the last years. Among these, the neurochemical theories have been the most suited, considering the dopaminergic and glutamatergic dysfunctions to be mainly responsible for psychotic symptoms. However, the lack of efficacy of the available drugs, namely antipsychotics, toward negative and cognitive symptoms led to hypothesize alternative approaches. In this regard, the neurodevelopmental theory of schizophrenia has emerged, proposing the association between the occurrence of environmental risk factors in early-life and the development of psychosis in late-life. In particular, exposure to early life stressing situations, such as pre- and peri-natal stress, has been suggested as a risk factor to d evelop psychopathologies in adulthood in people genetically predisposed. A crucial support in favor of this hypothesis came from neurodevelopmental animal models of schizophrenia, such as maternal malnutrition, maternal deprivation, maternal infections as well as post-weaning social isolation rearing. Moreover, data from these models, corroborated by clinical findings, indicate that oxidative and nitrosative stress play a crucial role in the etiopathogenesis of psychiatric disorders. In the present work, we reviewed the recent progress in literature regarding data available from animal models linking oxidative and nitrosative stress to psychiatric disorders in order to evaluate novel biomarkers of pathology as well as novel therapeutical targets.
Export Options
About this article
Cite this article as:
Mhillaj Emanuela, Morgese Grazia Maria and Trabace Luigia, Early Life and Oxidative Stress in Psychiatric Disorders: What Can we Learn From Animal Models?, Current Pharmaceutical Design 2015; 21 (11) . https://dx.doi.org/10.2174/1381612821666150105122422
DOI https://dx.doi.org/10.2174/1381612821666150105122422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoic Acid, a Lead Structure for Multi-Target-Directed Drugs for Neurodegeneration
Mini-Reviews in Medicinal Chemistry Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design Integration of <sup>18</sup>FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease
Current Alzheimer Research Advances in the Discovery of Novel Positive Allosteric Modulators of the α7 Nicotinic Acetylcholine Receptor
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Hot Topic:Therapeutic Agents of Lipids and Fatty Acids)
Current Organic Chemistry Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Exosomes: Structure, Biogenesis, Types and Application in Diagnosis and Gene and Drug Delivery
Current Gene Therapy Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy The Use of Stem Cells for the Treatment of Spinal Surgical Conditions.
Current Stem Cell Research & Therapy Can Trehalose Prevent Neurodegeneration? Insights from Experimental Studies
Current Drug Targets Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets Nasal Neuro EPO Could be a Reliable Choice for Neuroprotective Stroke Treatment
Central Nervous System Agents in Medicinal Chemistry Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer’s Mice and in Human Patients
Current Alzheimer Research Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Transient Cerebral Ischemia Leads to TGF-β2 Expression in Golgi Apparatus Organelles
Current Neurovascular Research